My PCR Releases New Resource on Treatment Free Remission (TFR)

My PCR Releases New Resource on Treatment Free Remission (TFR)

My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).

To keep patients at the center of our process, the Max team asked patient leaders and associations from around the world to send in their own questions about TFR. We compiled their submissions, identified common themes, and narrowed the field down to 10 key questions.

Download the My PCR Treatment-Free Remission FAQ (PDF)

The answers in the FAQ were provided by CML expert, Max Medical Advisor, and friend of the organization, Dr. Michael J. Mauro of Memorial Sloan Kettering Cancer Center. Thanks to his extensive knowledge and experience, the document offers valuable information for patients and providers alike.

This FAQ marks another new resource created by The Max Foundation’s My PCR initiative – a global effort to increase access to polymerase chain reaction (PCR) testing for CML.

The Max Foundation extends its thanks to all the generous sponsors who make the My PCR initiative possible:

  • Major Sponors: Bristol-Myers Squibb, Pfizer, Novartis, and Takeda Oncology
  • Supporting Sponsors: Asuragen, Cepheid, and Incyte

With their support we’re expanding access to critical diagnostics in low- and middle-income countries around the world.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Delivers First Treatment into Mozambique

    The Max Foundation Delivers First Treatment into Mozambique

    On November 1, 2019, the first shipment of treatment arrived at the hospital in Maputo, Mozambique. This is the first country Max Access Solutions, The Max Foundation’s patient-centered access model, has expanded into without a former access program in place.

  • Welcoming two new members to our Strategic Innovation Advisory Board

    Welcoming two new members to our Strategic Innovation Advisory Board

    Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD join the board this March

  • Invitation to iCMLf Forum for physicians attending ASH 2017

    Invitation to iCMLf Forum for physicians attending ASH 2017

    Join us at the iCMLf Forum for Physicians from Emerging Economic Regions on December 8th at ASH.